Tag:
atrial fibrillation
Latest Headlines
Latest Headlines
NICE nod for Xarelto as FDA panel mulls new use
The advisory panel is weighing evidence for a new, potentially lucrative use in patients with acute coronary syndrome.
FDA staff backs J&J's Xarelto for heart condition
The staffers' recommendation of approval comes ahead of Wednesday's advisory committee meeting on the expanded use of J&J and Bayer's Xarelto in ACS patients.
FDA review backs Xarelto for big new use in ACS patients
The anticoagulant won a thumbs-up from FDA reviewers ahead of Wednesday's advisory panel meeting, where FDA experts will weigh a lucrative new indication.
Boston Sci boasts stroke risk reduction for Watchman implant
Boston Scientific's Watchman device was found to reduce stroke risk in patients who can't take oral anticoagulants, a development that could help push the device toward U.S. availability.
Cardiome whips out budget ax as Merck dumps oral heart drug pact
Cardiome's long-running roller coaster ride with its atrial fibrillation drug vernakalant went into a steep descent this morning when the biotech announced that Merck ($MRK ) is dumping its...
Pradaxa, Xarelto gain reprieve as FDA delays Eliquis decision
Pfizer ( $PFE ) and Bristol-Myers Squibb ( $BMY ) will have to wait three more months for the FDA's latest word on Eliquis . The anticoagulant drug has some of the strongest data among a new cadre of...
NICE wants more data on Bayer's Xarelto
U.K. cost-effectiveness watchdogs aren't quite convinced about Bayer 's anti-clotting drug Xarelto . The National Institute for Health and Clinical Excellence says it's asking Bayer for more data on
FDA knocks Sanofi's Multaq down a peg
The once-brilliant prospects in Sanofi's ( $SNY ) Multaq have dimmed further. U.S. regulators, as expected, have taken action to keep patients with permanent atrial fibrillation from taking the French
EU brings Bayer's Xarelto into German market
Bayer has now gotten European regulators to sign off on selling its stroke prevention drug Xarelto in Germany, barely a month after the FDA approved the drug for sale in the U.S. The approval is a
ARCA cardio data analysis triggers brief spike in share price
Shares of ARCA biopharma ( $ABIO ) briefly went on a tear yesterday after the Broomfield, CO-based biotech reported some impressive data based on follow-up analysis of some aging late-stage data on its
